The divestment of Coloplast's brachytherapy business to Brachysales, Inc., now
known as Core Oncology, Inc., has been completed on 8 June 2007 in accordance
with the conditions described in Coloplast's stock exchange announcement no.
3/2007 of 20 February 2007.
The transaction includes an independent sales force as well as Coloplast's
manufacturing facility in Oklahoma, USA, also known as Mills
Biopharmaceuticals LLC.
The brachytherapy business is reported in the Group's income statement as net
profit from discontinued operations. The transaction has an insignificant
impact on Coloplast's results.
As the brachytherapy business encompassed approximately 1% of Coloplast's Group
revenue, the divestment will not affect the expectations for 2006/07 or the
long-term targets for 2012.
Lene Skole
Executive Vice President, CFO
Further information
Investors and financial analysts
Jørgen Fischer Ravn
Head of Investor relations
Tel. +45 3085 1308
E-mail: dkjfr@coloplast.com
Press and the media
Jens Tovborg Jensen
Head of Media relations
Tel. +45 3085 1922
E-mail: dkjto@coloplast.com
This announcement is available in a Danish and an English language version.
In the event of discrepancies, the Danish version shall prevail.
